Vijaya Diagnostic Centre Reports ₹178 Crore Profit and 200% Dividend for FY26

Financial Results for FY26

Vijaya Diagnostic Centre Ltd announced strong growth in its financial results for the year ended March 31, 2026. Standalone net profit reached ₹178.31 Crores on revenue that grew 21.16% to ₹790.59 Crores.

Consolidated annual income for FY26 increased by 19.34% to ₹835.00 Crores, with a net profit of ₹172.98 Crores.

The company also reported robust fourth-quarter (Q4 FY26) figures. Standalone total income for the quarter was ₹213.49 Crores, up 27.74% year-on-year, with a net profit of ₹52.65 Crores. Consolidated Q4 FY26 income stood at ₹221.78 Crores, yielding a net profit of ₹47.93 Crores.

The company has proposed a significant dividend of 200% (₹2 per share), reflecting confidence in its financial health. The statutory auditors issued an 'Unmodified Opinion' on the financial statements.

Significance of the Results

The strong results indicate Vijaya Diagnostic Centre's solid market position and operational efficiency. The double-digit growth in revenue and profit shows healthy demand for its services and effective business strategies, rewarding shareholders directly.

Company Background

Vijaya Diagnostic Centre is a prominent integrated diagnostic service provider in India, known for its extensive network of labs and radiology centres, particularly in Southern India. A key strategic move in recent years was the acquisition and subsequent amalgamation of Medinova Diagnostic Services Limited. This integration has helped consolidate its market presence and expand its operational footprint, reflected in the restatement of financial figures to show a larger, growing base.

What This Means for Shareholders

• Shareholders are set to receive a proposed dividend of 200% (₹2 per share).
• The company's standalone total equity has strengthened significantly, rising to ₹94,345.26 Lakhs from ₹78,013.71 Lakhs in the previous year (FY25).
• The operational scale of the company has expanded, partly due to the integration of Medinova.

Key Risks to Monitor

While performance is strong, investors should note potential challenges. Standalone non-current lease liabilities have increased substantially, rising from ₹27,254.72 Lakhs in FY25 to ₹37,805.95 Lakhs in FY26. Additionally, annual standalone total expenses have grown by 18.17% year-on-year, which could affect future margins if not managed well.

Competitive Landscape

Vijaya Diagnostic Centre operates in a competitive landscape alongside major players like Dr. Lal PathLabs Ltd and Metropolis Healthcare Ltd. These peers also focus on expanding their network and service offerings. The diagnostic sector is characterized by continuous investment in technology and capacity building. Vijaya's recent performance indicates it is effectively navigating this competitive environment, though managing rising costs and liabilities is key.

What to Watch Next

• Management's strategy for handling growing lease liabilities and controlling expenses.
• Performance in upcoming quarters, focusing on growth initiatives and cost management.
• Details on synergies from the Medinova amalgamation.
• Management guidance on future expansion plans or capital expenditure.
• The finalization and payout of the proposed 200% dividend.
• Competitor performance and market share in the diagnostic sector.